Eli Lilly is reducing the price of the highest doses of its popular drug Zepbound for folks who aren't using insurance.

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website starting early August, the U.S. drugmaker said on Monday. With the addition ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

INDIANAPOLIS — Eli Lilly filed lawsuits against compounding pharmacies and an Indianapolis weight loss company over the use of Zepbound and Mounjaro. On April 1, 2025, Lilly filed lawsuits against two ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for ... it will also be adding two new doses, as competition in the space continues to heat ...

Starting July 1, Zepbound will no longer be preferred ... Novo and Lilly have been locked in a fierce competition to dominate the obesity market, which is expected to reach $130 billion by the ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than AbbVie's 20%. Although both companies maintain a similar cash position (4% ...